Sunday - October 26, 2025
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
October 17, 2025
BOSTON, Massachusetts, Oct. 17 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer

*

Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI.

Treatment with osimertinib plus a p . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products